EASL-AASLD joint meeting on alcoholic liver disease and alcoholic hepatitis
Date: | 30-Sep-17 to 01-Oct-17 |
Location: | Pullman London St Pancras Hotel / London / United Kingdom |
Category: | Healthcare & Pharmaceuticals Conferences & Trade Fairs |
During the EASL-AASLD joint meeting on "Definition, therapeutic advances and clinical endpoints in alcoholic liver disease and alcoholic hepatitis" topics on public health, diagnostic definitions, therapeutic advances and clinical endpoints in alcohol related liver disease and alcoholic hepatitis will be discussed.
Alcohol related liver disease (ALD) is the most prevalent cause of advanced liver disease and liver related mortality in Western countries.
Research in ALD spans a wide spectrum from public health to basic science and despite being the ‘Cinderella’ disease area in hepatology, there have been a number of advances in recent years. We would like to take this opportunity to review with you the emerging data from clinical, translational and basic science studies in ALD. Furthermore, as pharmaceutical company interest in ALD begins to evolve we would encourage you to participate in discussions around the endpoints in clinical trials.
This conference will be a unique occasion to interact with experts and top-researchers, to get new ideas but also to contribute in the field of therapeutic development in ALD and alcoholic hepatitis.
Conference objectives:
--Attendees will be equipped with the most up-to-date evidence based practice information relevant to patients with alcohol related liver disease
--The attendees will be familiar with the most important controversies in the field and how the experts are addressing these issues
--The attendees will become aware of the rational behind new endpoints in clinical trials
--Debate and set endpoints in clinical trials
--Discuss and generate guidelines of best practice in alcohol related liver disease
The organisers: Prof. Philippe Mathurin, Prof. Vijay Shah, Prof. Gyongyi Szabo and Prof. Mark Thursz
Alcohol related liver disease (ALD) is the most prevalent cause of advanced liver disease and liver related mortality in Western countries.
Research in ALD spans a wide spectrum from public health to basic science and despite being the ‘Cinderella’ disease area in hepatology, there have been a number of advances in recent years. We would like to take this opportunity to review with you the emerging data from clinical, translational and basic science studies in ALD. Furthermore, as pharmaceutical company interest in ALD begins to evolve we would encourage you to participate in discussions around the endpoints in clinical trials.
This conference will be a unique occasion to interact with experts and top-researchers, to get new ideas but also to contribute in the field of therapeutic development in ALD and alcoholic hepatitis.
Conference objectives:
--Attendees will be equipped with the most up-to-date evidence based practice information relevant to patients with alcohol related liver disease
--The attendees will be familiar with the most important controversies in the field and how the experts are addressing these issues
--The attendees will become aware of the rational behind new endpoints in clinical trials
--Debate and set endpoints in clinical trials
--Discuss and generate guidelines of best practice in alcohol related liver disease
The organisers: Prof. Philippe Mathurin, Prof. Vijay Shah, Prof. Gyongyi Szabo and Prof. Mark Thursz
Exhibitors
Prof. Philippe Mathurin, Prof. Vijay Shah, Prof. Gyongyi Szabo and Prof. Mark Thursz
EIN News
provides powerful, real-time media monitoring, news aggregation & syndication services. Read the latest news about this topic. See:
- Autism News Today
- Brain Cancer News Today
- Breast Cancer News Today
- Breastfeeding News Today
- Conferences & Trade Shows Today
- Dental Industry Today
- Dietary Supplements News Today
- H1N1 News Today
- H7N9 Bird Flu News Today
- Health Insurance Exchanges News
- Healthcare Industry Today
- Healthcare Reform News Today
- Home Birth News Today
- Lung Cancer News Today
- MERS News Today
- Malaria News Today
- Marijuana News Today
- Mesothelioma News Today
- Pharmaceutical Industry Today
- Planned Parenthood News Today
- Prostate Cancer News Today
- SARS News Today
- Wellness News Today